Article

Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myeloma

2023-12-04

Abstract excerpt

<h4>SUMMARY</h4> Anti-CD38 antibody therapies have transformed multiple myeloma (MM) treatment. However, a large fraction of patients inevitably relapses. To understand this, we investigated 32 relapsed MM patients treated with daratumumab, lenalidomide, and dexamethasone (Dara-Rd; NCT03848676 ). Whole genome sequencing (WGS) before and after treatment pinpointed genomic drivers associated with early progression,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 72e5d791-89ca-5b90-84f5-5ed2b4774df8
DOI: 10.1101/2023.12.04.23299287

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myelomaDOI 10.1101/2023.12.04.23299287Read

Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myelomaSemantic proximity Read

CD38 biallelic loss is a recurrent mechanism of resistance to anti-CD38 antibodies in multiple myelomaSemantic proximity Read

Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myelomaSemantic proximity Read

Longitudinal multi-omic profiling uncovers immune escape and predictors of response in multiple myelomaSemantic proximity Read

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myelomaSemantic proximity Read

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma.Semantic proximity Read

Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myelomaSemantic proximity Read

Profound CD4+ T-Cell Reprogramming by Melphalan-Driven Oxidative Stress in High-Risk Multiple MyelomaSemantic proximity Read

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myelomaSemantic proximity Read

Multiple Myeloma Insights from Single-Cell Analysis: Clonal Evolution, the Microenvironment, Therapy Evasion, and Clinical ImplicationsSemantic proximity Read

Multiple Myeloma and Precursor Plasma Cell Disorders: From Emerging Driver Mutations to Current and Future Therapeutic StrategiesSemantic proximity Read

Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy.Semantic proximity Read